Targeting Once Inaccessible Phospho-Proteins With RePlex

TRANSFORMING HUMAN HEALTH ONE SMALL MOLECULE AT A TIME

Vividion Therapeutics is a small molecule company harnessing its expertise in target biology, chemistry, and mass spectrometry to transform the future of human health. They target disease-critical proteins that were once considered inaccessible with unmatched precision that limits the risk of off-target side effects. In oncology/immunology therapeutic areas they are driving preclinical studies focused on inhibiting a key signaling pathway implicated in tumorigenesis.

BLOWING PAST THROUGHPUT BARRIERS WITH REPLEX

To assess the ability of the small molecule to inhibit the pathway of interest, Vividion runs dose response curves to look for changes in the phosphorylation state and the abundance of key proteins using in vitro and in vivo models. However, monitoring quantitative phospho-protein changes is notoriously problematic and slow. High-throughput techniques like ELISA and HTRF are often unreliable and traditional Western blots, the best method for detecting phospho-proteins,
are time-consuming, low-throughput, and often don’t have the sensitivity required to detect low levels of phosphorylated proteins.

This case study reviews how by transferring their assays over to Simple Western™ with Jess™ combined with Jess’ RePlex™ module they are able to increase throughput and improve the accuracy of his phospho-protein quantification.